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INTRODUCTION 
Acute Myocardial Infarction is the leading cause of mortality in 
both developed and developing countries (Rogers WJ et.al1., Kesteloot 
H et.al2.,)  
Acute coronary syndromes are emerging out in epidemic 
proportions through out the world. Factors contributing to death 
following Acute Myocardial Infarction are many. 
These factors relate mainly to electrical disturbances in the form 
of Arrhythmia (Carmeliet E3, Thompson CA4) and mechanical 
disturbances in the form of pump failure ( Hochman et. al5., Bertrand M 
et. al6.). 
Most sudden deaths in Acute Myocardial Infarction occur within 
one hour due to ventricular fibrillation and also due to left ventricular 
failure when there is an extensive injury. ( Lewis EF et. al7.) 
Rest of the deaths following Myocardial Infarction occur within 
first one week and death cannot be predicted and occurs suddenly. 
Hence many trials have been conducted to identify markers that would 
be helpful to predict the risk of such adverse cardiac events. 
Many trials have used serum Magnesium level,(Milionis HJ 
et.al8.,) C-Reactive Protein levels, (Ridker PM, Morrow DA et.al9.,) 
Malonyldialdehyde, (Pol Merkuriusz Lek10) white blood cell count 
(Comparan Nunez. A et. al10.,) as a predictor for mortality and morbidity 
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following Acute Myocardial Infarction and risk of developing adverse 
cardiac events like sudden cardiac death and congestive heart failure  
THIS STUDY IS ONE OF SUCH KIND IN THAT IT TRIES TO 
VALIDATE THE PROGNOSTIC ROLE OF SERUM URIC ACID LEVEL 
FOLLOWING ACUTE MYOCARDIAL INFARCTION. (Kojima S., 
Sakamoto, Am .J Cardiol . 2005 Aug, Sakai H University of Medical 
Science, Otsu, Japan, Niizeki T., J. Cardiology 2006 May, Joshua M, 
Circulation 2003: American Heart Association.) 
Previous studies have established that serum uric acid levels 
reflect circulating xanthine oxidase activity and oxidative stress 
production following Acute Myocardial Infarction. 
Free radicals produced in large amounts during myocardial 
ischemia and reperfusion take part in the degradation of cellular and 
subcellular membrane structures. The source of oxygen radicals in 
ischemic myocardium are Neutrophils recruited into the necrotic 
region as well as metabolic transformation of Hypoxanthine and 
Xanthine to Uric acid (Domonsky L et. al10.) 
Thus it is evident that elevated Uric acid levels is a good marker 
of oxidative stress and useful to assess the prognostic events in Acute 
Myocardial Infarction. 
This forms the basis of the study. 
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AIMS OF THE STUDY 
 
1. To assess the prognostic significance of serum Uric acid level in 
Acute Myocardial Infarction. 
2. To correlate levels of Uric acid in terms of short term mortality 
3. To correlate serum Uric acid levels with incidence of cardiac 
failure 
4. To validate the relation between Quantitative serum Uric acid 
level on admission and Killip’s class status on Acute Myocardial 
Infarction. 
5. To know whether the incidence of Arrhythmias bears a relation 
with serum Uric acid level in Acute Myocardial Infarction. 
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REVIEW OF LITERATURE 
 Ischemic Heart Disease in the generic  designation for a 
spectrum of disorders resulting from imbalance between the 
myocardial need for oxygen and the adequacy of blood supply11. In 90-
95% of cases the reduction in the coronary blood flow is related to 
atherosclerotic narrowing or the  subepicardial coronary trunks. 
Coronary vasospasm alone or superimposed on atherosclerotic 
narrowing may contribute to the reduction of flow12. 
 Depending upon the rate of development of the arterial 
narrowing and its ultimate severity, four basic clinico  pathologic 
syndromes may result.  
 They are   
1. Myocardial Infarction 
2. Angina pectoris. 
3. Chronic Ischemic Heart Disease 
4. Sudden Cardiac Death – which may be superimposed on 
any of the three conditions. 
MYOCARDIAL  INFARCTION : 
 This is the catastrophic frequently fatal form of Ischemic Heart 
Disease that usually results from precipitous reduction or arrest of a 
significant portion of coronary flow. 
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 In great majority of cases wide spread severe coronary 
atherosclerosis of the coronary arteries underly Myocardial Infarction. 
In addition some sudden event such as coronary thrombosis must 
unfavorably alter the precarious balance. Alternatively the myocardial 
supply can be suddenly reduced by a superimposed vasospasm. 
Congenital abnormalities such as anomalous origin of left anterior 
descending coronary artery from the pulmonary artery may cause 
myocardial ischemia and infarction. But it is very rare. 
 Coronary atherosclerosis creates a disparity between myocardial 
needs  and supply. Myocardium extracts  a high and virtually  fixed 
fraction of oxygen from the coronary arterial blood. Atherosclerotic 
arteries can not dilate and so incapable of adjusting to the demands. 
Transient deficit of  oxygen can be  compensated by anerobic 
glycolysis with the production of lactate13. If the imbalance is not 
transient, it passes from the reversible ischemic injury to the 
irreversible ischemic necrosis. Depending upon the rate of 
development of the arterial narrowing and its ultimate severity, three 
basic clinico pathologic syndromes occur namely Angina pectoris, 
Acute  coronary insufficiency  & Myocardial  Infarction. 
 Angina pectoris is a clinical syndrome resulting from transient 
reversible myocardial ischemia and is produced by any effort which 
increases the metabolic demands of the myocardium beyond the 
capacity of the coronary circulation. The  anginal pain is  due to 
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accumulation of certain metabolites that are formed in ischemic 
working muscle. It is diagnosed clinically by the typical history of the 
site, the character and duration of pain, the site of its radiation and by 
its characteristic precipitating and relieving factors. Here the 
Electrocardiogram will be usually normal. Ischemic changes can be 
demonstrated only by the stress Electrocardiogram. 
  Acute coronary insufficiency is a syndrome which is 
intermediate between Angina pectoris and Myocardial Infarction. In this 
condition, physiologically the coronary circulation is insufficient to 
meet the full demands to the myocardium even at rest, yet sufficient to 
prevent myocardial necrosis. Clinically it may be acute or sub acute in 
onset. The important feature is that the pain may occur even at rest and 
the duration  of pain is prolonged than that of the anginal pain and 
precipitated on exertion and not relieved by rest. There will not be any 
evidence of myocardial cell necrosis. It can be diagnosed by the 
characteristic ischemic changes in the Electrocardiogram. 
Acute  Myocardial Infarction  is a pathologic process resulting 
from the reduced perfusion of a  segment of the myocardium such that 
irreversible injury occurs. The infarct may be subendocardial or 
transmural. 
Subendocardial infarct refers to a multifocal, non-confluent   
areas of ischemic necrosis, often distributed circumferentially. This 
does not extend beyond. The inner one third to one half of the 
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thickness of the left  ventricular wall. The patients with this type of 
infarction are more prone for cardiac arrhythmias. Coronary 
thrombosis is not found in more than 10% such cases14. 
Transmural  infarct refers to a confluent area of ischemic 
necrosis extending at some point from the subendocardium to the 
epicardium or subepicardial fat. Coronary thrombosis is usually 
present in 90-95% of these cases. 
EPIDEMIOLOGY : 
The incidence of fatal Myocardial Infarction progressively rises 
with age to peak in the 55-65 years old group.  
Myocardial Infarction occur in younger individuals, even in the 
third decade of life, particularly when predispositions to 
atherosclerosis, Hypertension , diabetes,  familial  hypercholestrolemia 
& other causes of hyperlipoproteinemia are present. 
Virtually  throughout life, males  are at significantly greater risk 
than females, the differential progressively declining with advancing 
age. Except for those having some predisposing atherogenic 
condition, women are remarkably protected against Myocardial 
Infarction during reproductive life. Women using oral  contraceptives 
have 3 to 4 fold greater risk than non users and this increased risk 
does not appear to be related to the duration of  use15. 
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CIGARETTE SMOKING:    
  Cigarette smoking particularly in combination with other risk 
factors has been shown to have a strong and consistent association 
with increased incidence of atherosclerosis, by increasing 
catecholamine stimulation which enhances platelet aggregation and 
peripheral lipid mobilization and decreasing the ratio of High Density 
Lipoprotein (HDL) to Low Density Lipoprotein (LDL) 16. 
STRESS AND PERSONALITY : 
  Stress is associated with increased catecholamine  secretion 
and surges mental stress may thus be a aggravating factor. 
  Type A individuals who are anxious, aggressive, impatient, 
competitive, always in a frustrate mood are more prone for IHD17. 
SEDENTARY LIFE  STYLE : 
  Exercise conditioning when regularly employed, reduces the rate 
of fatal Heart disease18. 
  It is proved that HDL level increases with exercise, & also 
augments fibrinolytic response and there by  provide a potential 
protective mechanism against development of thrombi  within coronary 
arteries19. 
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DIABETES  MELLITUS : 
  It has been shown that a diabetic patients serum can cause 
hyperplasia of smooth muscle cells. Furthermore, high blood sugar is 
often associated with obesity, hypertension, increased  triglycerides, 
Low HDL, increased LDL and abnormal platelet adhesiveness. Diabetes 
is said to double the risk of ischemia in men and women 3-4 times.  
Silent Myocardial Infarction is thought to occur with increased 
frequency in diabetes and should be suspected whenever symptoms of 
left ventricular failure appear suddenly20. 
CORONARY BLOOD FLOW : 
  The blood flow in coronary arteries resembles that in other 
regions in being dependant  on the blood pressure and on the vascular 
resistance of the arteries and the arterioles. 
  A distinctive feature of the coronary circulation is that the 
arteries are compressed by the contracting myocardium during 
systole. Consequently coronary blood flow occurs  mainly during 
diastole21. 
  The normal coronary circulation is dominated and controlled by 
the myocardial requirements for oxygen. This need is met by the 
heart’s ability  to vary coronary   vascular resistance and therefore 
blood flow. Considerably while the myocardium extracts a high and 
relatively fixed percentage of oxygen. 
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  The large epicardial vessels serve as conduits in healthy 
persons, although they are capable of constriction and relaxation they 
are referred as the conductance vessels. 
  The intramyocardial vessels normally  exhibit striking changes in 
tone and are therefore referred as resistance vessels. 
  Hence with exercise and emotional stress, the changing oxygen 
needs affect coronary vascular resistance and in this manner regulate 
the supply of blood and oxygen (metabolic  regulation). 
  These same vessels adapt to physiologic alterations in blood 
pressure in order to maintain coronary blood flow at levels appropriate 
to myocardial needs. (Auto regulation). 
  The frequencies of the critical narrowing of each of the three 
main arterial trunks and the associated myocardial lesions are as 
follows22 : 
a) Left Anterior descending            :  Anterior wall of left ventricle near 
coronary  artery (40-50%)  apex, anterior two thirds of 
  Inter ventricular septum. 
b) Right coronary  artery     : Posterior wall of left ventricle,                      
(30-40%)             Posterior one third of inter  
   ventricular septum 
c) Left circumflex  coronary        :  Lateral wall of left ventricle. 
                  artery (15-20%)  
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REVISED DEFINITION OF MYOCARDIAL INFARCTION: 23 
Criteria for acute evolving or recent MI : 
  Either one of the following criteria satisfies the diagnosis for an 
acute, evolving or recent MI : 
1. Typical rise and gradual fall (troponin) or more rapid rise and fall 
(CK- MB) of biochemical markers of myocardial necrosis with at least 
one of the following : 
a) Ischemic symptorns. 
b) Development  of pathologic Q  waves on the ECG reading. 
c) ECG changes indicative of ischemia (ST segment 
elevation or depression)  
d) Coronary  artery intervention (eg : coronary angioplasty) 
2. Pathological findings of acute MI . 
Criteria for established MI : 
  Either of the following criteria satisfies the diagnosis for 
established MI : 
1. Development of new pathological Q waves on serial ECG 
readings. The patient may or may not remember previous 
symptoms. Biochemical markers of myocardial necrosis may 
have normalized, depending on the length of time that has 
passed since the infarct developed. 
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2. Pathological findings of a healed or healing MI. 
  Several researchers all over the world have been attempting for 
decades to establish those criteria that best define patients with a 
poorer prognosis. Taken in toto, the various studies and articles 
published in the literature may be classified conveniently into two 
major headings: 
1. Criteria obtained at the initial physician contact including patient 
characteristics (eg : age, gender), details of history, the initial 
clinical examination findings . 
2. The laboratory parameters obtained on admission. 
CHEST PAIN : 
   Despite the recent advances in the laboratory diagnosis of Acute 
Myocardial Infarction (AMI), the history remains of substantial value in 
arriving at a diagnosis. A prodrome of chest discomfort can usually be 
elicited in 20 to 60% of patients with AMI. 24 
   The pain of AMI resembles that of classic Angina pectoris, 
except that is more severe, occurs at rest or with lesser activity than 
usual, lasts longer (more than 30 minutes) is associated with more 
systemic symptoms (eg : diaphoresis, nausea) and not relieved by rest 
or nitrates. On occasion it radiates to the arms. Less common sites of 
radiation include the abdomen back, lower jaw, and neck. The pain may 
radiate as high as the occipital area but not below the umbilicus. 
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   In an analysis of the atypical presentations of AMI, Bean et.al., 
lists the following : 25 
1. Congestive Heart failure.  
2. Classic angina pectoris (not severe or prolonged). 
3. Atypical locations of the pain. 
4. Central nervous system manifestations, resulting from a reduced 
cardiac output, resembling a stroke. 
5. Apprehension and nervousness. 
6. Sudden Mania and Psychosis. 
7. Syncope 
8. Over whelming weakness. 
9. Acute indigestion  
10. Peripheral embolism.    
   To this list must be added those patients with “silent” AMI – who 
have had no symptoms at onset. Such presentations are commoner in 
diabetes and hypertensives, and both of these conditions are also 
associated with an increased mortality. 26 
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PHYSICAL FINDINGS : 
   Most patients are anxious and restless, attempting 
unsuccessfully to relieve the pain by moving about in bed, altering 
their position, and stretching. Pallor associated with perspiration and 
coolness of the extremities occurs commonly. About one fourth of 
patients with Anterior Infarction have manifestations of sympathetic 
nervous system hyperactivity (tachycardia or hypertension) and upto 
one half with Inferior Infarction show evidence of para sympathetic 
hyperactivity (bradycardia or hypotension). 27 
   The apical impulse may be difficult to palpate. S3, S4 gallop 
sounds, decreased intensity of first Heart sound and paradoxical 
splitting of second Heart sound may be there. A transient mid systolic 
or late systolic apical systolic murmurs may be heard in mitral area. 
Pericardial friction rub  is heard at some time in the course of disease. 
The carotid pulse is often decreased in volume, reflecting reduced 
stroke volume. In most transmural MI patients, systolic pressure 
declines by approximately 10-15 mmHg from the pre infarction state.   
SERUM CARDIAC BIOMARKERS : 
   These  cardiac markers are released into the blood in large 
quantities from necrotic heart muscle after MI. 
   Creatinine  phosphokinase (CK) rises  within 4 to 8 hour and 
generally returns to normal by 48 to 72 hrs . An important draw back of 
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total CK measurement is its lack of specificity for STEMI (ST Elevation 
MI), as CK may be elevated with skeletal muscle trauma.  
   Creatinine  phosphokinase  MB isoenzyme (CK-.MB) has the 
advantage over total CK that is not present in significant 
concentrations in extra cardiac tissue and therefore is more specific. 
However, cardiac surgery, myocarditis,  electrical cardioversion often 
result in elevated serum levels of CK-MB. A ratio ( relative index) of CK- 
MB mass : CK activity > 2.5 suggests but is not diagnostic of a 
myocardial rather than a skeletal muscle source for the CK – MB 
elevation. 28 
   Cardiac specific troponin T ( cTnT) and cardiac specific troponin 
I  (cTnI) are not normally detectable in the blood of healthy individuals, 
but may increase after STEMI to levels > 20 times higher than the upper 
reference limit. They are now the preferred biochemical markers of MI. 
Levels of cardiac troponins remain elevated for 7 to 1o days   after 
STEMI. 
   Myoglobin is released into the blood within a few hours of the 
onset of STEMI. But it lacks cardiac specificity, because it is rapidly 
excreted in the urine, So blood levels return to the normal range with in 
24 hours of the onset of infarction. 
   Serum lipids are often determined in patients with STEMI. During 
the first 24 to 48 hours after admission, total Cholesterol and HDL 
cholesterol remain at or near baseline values, generally fall after 48 
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hours. The fall in  HDL cholesterol after STEMI is greater than total 
cholesterol. Elevation of white blood cell count (Polymorphonuclear  
Leukocytosis) appears within  a few hours and peaks at 2 to 4 days. 
   Erythrocyte Sedimentation Rate peaking during the first week 
and elevated for 1 or 2 weeks. Other markers like C-Reactive Protein, 
LDH, SGOT also elevated. 29 
CARDIAC IMAGING : 
   Two dimentional echocardiography, Doppler echocardiography , 
myocardial perfusing  imaging with Thallium 201 or 99mTc – Sestamibi 
scan useful in Acute MI. Radio nuclide ventriculography carried out 
with 99mTc labeled red blood cells frequently demonstrates wall motion 
disorders and ejection fraction in MI patients. 30 
HEMODYNAMIC ABNORMALITIES: 
  In 1976, Swan, Forrester, and their associates measured the 
cardiac output and wedge pressure simultaneously in a large series of 
patients with acute Myocardial Infarction and identified four major 
hemodynamic subsets of patients. 31 
1. Patients with normal perfusion and without pulmonary 
congestion (normal cardiac output and normal wedge pressure). 
2. Patients with normal  perfusion and pulmonary congestion. 
(normal cardiac output and elevated wedge pressure). 
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3. Patients with decreased perfusion but without pulmonary 
congestion. (reduced cardiac output and normal wedge 
pressure). 
4. Patients with decreased perfusion and pulmonary congestion. 
(reduced cardiac output and elevated wedge pressure). 
  This classification which overlaps with a crude clinical 
classification proposed earlier by Killip and Kimball, has proved to be 
quite useful, but it should be noted that patients frequently pass from 
one category to another with therapy and sometimes even 
spontaneously.  
 
  HEMODYNAMIC CLASSIFICATION OF PATIENTS WITH 
AMI BY KILLIP CLASSIFICATION :  
 
Class Definition31 
I Patients with MI and no evidence  of  Heart failure. 
II Patients with MI, Early Heart failure as manifested by 
bibasilar rales, and at times S3  gallop. 
III Patients with MI, features of pulmonary edema (Rales >1/2 
lung fields) 
IV Patients  with MI, cardiogenic  shock. 
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Subset Based on invasive monitoring Definition32 
I Normal hemodynamics 
PCWP <18, CI >2.2 
II Pulmonary Congestion 
PCWP >18, CI >2.2 
III Peripheral hypo perfusion 
PCWP <18,CI<2.2 
IV Pulmonary congestion and peripheral hypo perfusion 
PCWP>18, CI <2.2 
PCWP Æ Pulmonary Capillary Wedge Pressure  
CI        Æ Cardiac Index. 
HEART FAILURE : 
   Heart failure is a state when the heart cannot maintain an 
adequate cardiac output or can do so only at the expense of an 
elevated filling pressure. 
   Heart failure is frequently due to coronary artery disease, tends 
to affect elderly   people and often leads to prolonged disability. 
   Cardiac output is a function of preload, afterload and myocardial 
contractility. The primary abnormality in Heart failure is impairment of 
ventricular function leading to a fall in cardiac output. This activates 
counter regulatory neurohormonal mechanisms that in normal 
physiological circumstances would support cardiac function, but in the 
setting of impaired ventricular function can lead to a deleterious 
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increase in both afterload and preload. A vicious circle may be 
established because any additional fall in cardiac output will cause 
further neurohormonal  activation and increasing peripheral vascular 
resistance. 33 
   Stimulation of the renin-angiotensin-aldosterone system leads to 
vasoconstriction, salt and water retention and sympathetic activation 
mediated by angiotensin  II, which is a potent constrictor  of arterioles 
both in the kidney and systemic circulation. Salt and water retention is 
promoted by release of aldosterone, endothelin (a potent 
vasoconstrictor peptide with marked effects on the renal vasculature) 
and in severe Heart failure. Anti Diuretic Hormone (ADH), Natriuretic 
peptides are released from the atria in response to atrial stretch, and 
act as physiological antagonists to the fluid conserving effect of 
aldosterone and extremely useful in diagnosis, prognosis and 
monitoring therapy. 
   After Myocardial Infarction, cardiac contractility is impaired and 
neurohormonal activation may lead to hypertrophy of non–infarcted 
segments  with thinning, dilatation and expansion of the infarcted 
segment. (remodeling ). This may lead to deterioration in ventricular 
function and worsening heart failure. 
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NEURO ENDOCRINE FACTORS KNOWN TO BE INCREASED 
IN PATIENTS  WITH HEART FAILURE : 34    
   Norepinephrine   Endothelin 
   Epinephrine    β – endorphins 
   Renin activity   Calcitonin gene related peptide 
   Angiotensin  II   Growth hormone 
   Aldosterone    Cortisol 
   Arginine vasopressin  Tumour necrosis factor - α 
   Neuropeptide Y   Neurokinin – A 
   Vaso active intestinal peptide Substance – P 
   Prostaglandins   Adrenomedullin 
   Atrial naturiuretic factor 
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MECHANISMS OF CHRONIC CONGESTIVE HEART FAILURE 
DUE TO CORONARY ARTERY DISEASE: 35 
Severely depressed LV function : 
MYOCARDIAL INFARCTION : 
1. Large (usually Anterior) transmural infarct with severe 
depression of LV function (EF<30-35%) due to acute extensive 
loss of myocardium. 
2. Multiple infarcts with extensive myocardial fibrosis (not always 
clinically  recognized)  resulting in severe reduction in systolic 
function (Ischemic  cardiomyopathy) 
3. Prior myocardial infarction with mitral regurgitation (systolic 
function mildly to severely decreased). 
4. LV aneurysm 
5. Late post MI systolic dysfunction, known as LV remodeling. 
MYOCARDIAL ISCHEMIA : 
1. Extensive regions of hibernating LV myocardium – viable but 
ischemic (low coronary blood flow) zones of LV systolic 
dysfunction often accompanied by reversible and irreversible 
dysfunction fibrosis or scar. 
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2. Ischemic papillary muscle dysfunction resulting in mitral 
regurgitation.    
Normal or mildly  depressed LV function: 
1. Diastolic dysfunction related to ischemia and or LV hypertrophy / 
fibrosis.  
2. Severe mitral regurgitation 
3. Ventricular septal defect (rare) 
Any of above superimposed on cardiac distress related to other 
etiologies : 
1. Valvular heart disease 
2. Preexisting non  ischemic  cardiomyopathy. 
MORTALITY : 
   Studies involving large number of patients have revealed wide 
variations in the time elapsed between symptom onset and arrival at 
the hospital. Researchers have investigated for a relationship between 
this delay and inhospital mortality. However there are certain 
complexities in their relationship as follows . 
   Most sudden deaths in AMI occur due to ventricular Arrhythmias 
and this risk is maximum in the first hour after symptom onset. With 
each subsequent hour, the risk decreases, giving rise to the 
paradoxical situation where a patient who presents late to the hospital 
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has a lesser risk of sudden death than one who presents early for 
treatment. 40-60% of patients have some degree of left ventricular 
dysfunction at presentation if untreated, this may go on to a 
cardiogenic shock, the commonest cause of  inhospital death in AMI. 
This implies that the patient who presents sufficiently early for shock 
to be treated or prevented has a better  prognosis . 
   Established beyond reasonable doubt that the patient  who 
presents early enough for thrombolysis has large benefits from 
reperfusion, vastly improving the prognosis. 
   Raitt et.al., have shown that each 30 minute delay is associated 
with a 1% increase infarct size. 36 Julian D.G analyzing the results of 
five mortality trials, concluded that gaining about one hour prior to  
thrombolysis decreases mortality by about 17%.37 Even for patients 
presenting at later than  this   window period of 6 hours, thrombolysis 
can be beneficial, compared to those that do not receive such 
treatment. Yusuf et al., showed a 22% reduction in mortality for those 
treated at 12-24 hours. The ISIS – 2 trial extended the concept of 
beneficial late perfusion with its results revealing a significant benefit 
beyond 6-12 hours, and even 12-24 hours.38 These findings are 
confirmed by the ISIS- 3 and EMERAS trials. 39 The newer agents such 
as t–PA, Urokinase or even emergency coronary angioplasty may 
achieve better late reperfusion than Streptokinase. 40 
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GENDER  RELATED DIFFERENCES IN PROGNOSIS : 
   Unlike in previous years, the incidence of AMI in women is 
increasing. AMI in women has certain peculiarities. Women are mostly 
older than men at presentation and are more likely to have atypical 
pain, Hypertension, Diabetes, unstable angina, hyperlipidemia, 
congestive cardiac failure or silent infarctions are all commoner in 
women. Women more frequently have non – Q AMI and tend to present 
later to hospital. 41 Of interest after STEMI, younger women but not 
older women have higher rates of inhospital mortality than  men of the 
same age. 
The pathogenic mechanisms different in women include : 42 
¾ A greater incidence of vasospastic and micro circulatory angina. 
¾ Different plaque components (more cellular and fibrous tissue). 
¾ Different endothelial tone due to hormonal influences.    
¾ Different hemostasis (higher fibrinogen and factor VIII levels. 
DIABETES AND ITS EFFECTS ON PROGNOSIS : 
   The early pioneering studies an AMI, especially those by killip 
and Norris suggested that the presence of diabetes had a significant 
effect on the mortality. The famous Framingham Heart  study indicated 
that diabetes increased the risk of death in women, but not men, after a 
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first AMI. They tend to have larger infarcts, and show a greater 
incidence of shock, cardiac failure and metabolic problems.43 
HYPERTENSION AND ITS EFFECT ON PROGNOSIS : 
   The GISSI – 2 trial one of the largest ever series of AMI patients 
(11,843 patients, of which 3306 were hypertensive) investigated the 
prognostic value of hypertension in those receiving thrombolysis. 
Their results show a significantly higher mortality for hypertensives  
LV failure and recurrent ischemic events were also more common 
among hypertensives. 44 
PULSE, BLOOD PRESSURE AND ITS EFFECT ON 
PROGNOSIS: 
   The SPRINT study group, reporting in October 1995, found an 
increasing mortality with increasing heart rates at admission from less 
than 70 to more than 90 / minute. At even higher heart rates, the 
increasing trend of mortality was confined to those with heart failure. A 
combination of a rate more than 90 with a systolic pressure less than 
120 mmHg was a powerful predictor of inhospital mortality. 
   Patients develop cardiogenic shock when more than 40% of the 
myocardium is destroyed. Beyond the immediate phase, cardiogenic 
shock is the commonest cause of mortality. The hospital mortality for 
cardiogenic shock is in the region of 60-80%. The incidence of 
ventricular arrhythmias and heart block was found to be higher in 
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these patients. (Killip et.al.,) By multivariate analysis of their  cohort of 
845 patients. Hands et.al., found that the predictors of cardiogenic 
shock included age >65, ejection fraction <35%,  peak CK-MB value 
more than 160 IU/ L and a history of diabetes or prior infarction. 45 
PROGNOSTIC PARAMETERS AT HOSPITAL ADMISSION IN 
PATIENTS PRESENTING WITH ACUTE  MYOCARDIAL  
INFARCTION : 46 
Parameters Effect on prognosis 
Age  Prognosis worsens with 
increasing age  
Sex Women have a worse prognosis 
than men  
Heart Rate Heart rate >100/mt indicates a 
poor prognosis  
Cardiogenic shock A very high early mortality 
Congestive Heart failure Indicates a poor prognosis even 
when treated successfully  
ST segment deviation  The more ST segment deviation 
or Q wave formation, the larger 
the infarct and the worse 
prognosis. 
Enzymes Not admission levels, but 
evolving rise in cardiac enzymes 
estimate infarct size. 
Troponin levels  Elevated admission troponin – I 
or troponin – T indicates a worse 
prognosis even in the absence of 
rising CPK or CK-MB. 
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URIC ACID BIOCHEMISTRY : 
   Uric acid is the final breakdown product of Purine metabolism. 
Most mammals have the ability to catabolize   purines to allantion, a 
more water soluble end product. 
   Purines such as adenosine and guanine from the breakdown of 
ingested nucleic acids or from tissue destruction are converted into 
uric acid primarily in the liver. Uric acid is transported in the plasma 
from the liver to the kidney, where it is filtered by the glomerulus. 
Reabsorption of 98-100% of the uric acid in the glomerular filtrate 
occurs in the proximal tubules. Small amounts of uric acid are secreted 
by the distal tubules into the urine. This route accounts for about 70% 
of the daily uric acid excretion. The remainder is excreted  into the GI 
tract and degraded by bacterial enzymes. Uric acid is produced only in 
tissues that contain xanthine oxidase, primarily the liver and small 
intestine. 
   Nearly all of the uric acid in plasma is present as monosodium 
urate. At the pH of plasma, Urate is insoluble; at concentrations greater 
than 6.4 mg/dl the plasma is saturated. As a result, urate crystals may 
form and precipitate in the tissue. In the urine at pH<5.7, uric acid 
crystals may form. 
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HUMANS CATABOLIZE PURINES TO URIC ACID : 47 
   Humans convert the major purine nucleosides adenosine and 
guanosine to the excreted end product uric acid via the intermediates 
and reactions. Adenosine is first deaminated to inosine by adenosine 
deaminase. Phosphorolysis of the N-glycosidic bonds of inosine and 
guanosine, catalyzed by purine nucleoside phosphorylase releases 
ribose 1 – phosphate and a purine base. Hypoxanthine and guanine 
next form xanthine in reactions catalysed by xanthine to uric acid in a 
second reaction catalyzed by xanthine oxidase and guanase 
respectively. Xanthine is then oxidised to uric acid in a second reaction 
catalyzed by xanthine oxidase. Thus xanthine oxidase provides a 
potential locus for pharmacologic intervention in patients with 
hyperuricemia. 
   Net excretion of total uric acid in normal humans averages 400-             
600 mg/24hr. In mammals other than higher primates, the enzyme 
uricase cleaves uric acid, forming the highly water soluble end product 
allantion. However, since humans lack uricase, the end product of 
purine catabolism in man is uric acid. Amphibians, birds and reptiles 
also lack uricase and excrete  uric acid and guanine as end products of 
purine catabolism. 
     Humans catabolize purines to week acid uric acid. (pk 5.8) 
which depending on urinary  pH, exists as the relatively insoluble acid 
(at acidic pH) or its more soluble sodium urate  salt. Urate crystals are 
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diagnosic  of gout, a metabolic disorder of purine catabolism. Other 
disorders include Lesch – Nyhan syndrome, von Gierkes disease and 
hypouricemias. 
HYPERURICEMIA : 
   It can result from increased production or decreased excretion of 
uric acid or from a combination of the two processes.  Hyperuricemia 
is defined as a plasma concentration of > 7mg/dl in males and > 6mg/dl 
in females. 
 CLASSIFICATION OF HYPERURICEMIA BY 
PATHOPHYSIOLOGY : 48 
URATE OVERPRODUCTION :  
¾ Primary idiopathic  
¾ HPRT deficiency  
¾ PRPP synthetase  
Over activity  
¾ Hemolytic processes 
¾ Lymphoproliferative 
Diseases 
¾ Myeloproliferative 
Diseases 
¾ Glycogenesis III, V, VII, 
¾ Rhabdomyolysis 
¾ Exercise 
¾ Alcohol 
¾ Obesity 
¾ Purine rich diet  
¾ Polycythemia vera 
¾ Psoariasis  
¾ Pagets disease 
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DECREASED URIC ACID EXCRETION: 
¾ Primary idiopathic  ¾ Lead intoxication 
¾ Renal insufficiency  ¾ Hyperparathyroidism 
¾ Polycystic kidney disease ¾ Hypothyroidism 
¾ Diabetes insipidus ¾ Toxaemia of pregnancy 
¾ Hypertension  ¾ Bartters syndrome  
¾ Acidosis 
                 Lactic acidosis 
Diabeticketo                 
acidosis 
¾ Down syndrome  
¾ Drug ingestion 
¾ Salicylates (>2g/d) 
¾ Starvation ketosis                Diuretics 
¾ Berylliosis               Alcohol 
¾ Sarcoidosis               Levodopa 
             Ethambutol 
                  Pyrazinamide 
            Cyclosporine 
COMBINED MECHANISM : 
¾ Glucose  - 6 – Phosphatase deficiency 
¾ Fructose – 1 – Phosphate aldolase deficiency 
¾ Alcohol  
¾ Shock 
Note : HPRT : Hypoxanthine Phospho Ribosyl  Transferase  
           PRPP : Phospho Ribosyl  Pyro Phosphate. 
   Accelarated purine nucleotide degradation can also cause 
hyperuricemia i.e with conditions of rapid cell turnover, proliferation or 
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cell death, as in Leukemic blast crisis, cytotoxic theraphy for 
malignancy, hemolysis or rhabdomyolysis. Hyperuricemia can result 
from excessive degradation of muscle ATP after strenuous physical 
exercise or status epilepticus.   
   Hyperuricemia of Myocardial Infarction, smoke inhalation and 
acute respiratory failure may also be related to accelerated  breakdown 
of ATP. 
Secondary causes of hyperuricemia : 49 
1. Obesity 
2. Dyslipidemia (Usually type 4) with raised VLDL and normal 
cholesterol levels; hypercholestrelemia with increased LDL 
cholesterol  and Low  HDL cholesterol. 
3. Hypertension  
4. Insulin resistence  with hyperinsulinemia and impaired glucose 
tolerance. 
5. Ischemic Heart Disease. 
OXIDATIVE  STRESS : 
   There is evidence that oxidative stress is increased both 
systemically and in the myocardium  of patients with Heart failure.50 
Increased oxidative stress may be due to reduced antioxidant capacity 
of the increased production of reactive oxygen species, which may be 
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a consequences of mechanical strain on the myocardium or 
stimulation by neuro hormones and inflammatory cytokines. Possible 
sources of increased production of reactive oxygen species include 
the mitochondria, xanthine oxidase and NADPH oxidase.51 Reactive 
oxygen species can stimulate myocyte hypertrophy, reexpression of 
fetal gene programs and apoptosis in cardiac myocytes in culture.52 
   There is no evidence that uric acid is toxic to myocardium. 
Hyperuricemia may be a marker of coincident cardiac disease, but not 
a causal risk factor. The increased plasma uric acid concentration 
observed  in patients with ischemic heart disease could  arise from 
upregulated vascular adenosine synthesis associated with ischemia 
and the subsequent degradation of adenosine to uric acid. The 
relationship of urate to endothelial function is complex.  Plasma uric 
acid accounts for 60% of the free radical scavenging activity in human 
plasma.  It interacts with peroxynitrite to form a stable Nitric oxide 
donar, so promoting vasodilaiton and reducing the potential for 
peroxynitrite induced oxidative damage. Conversely it could have an 
adverse effect on endothelial function by promoting leukocyte 
adhesion  to the endothelium.53 
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URIC ACID PREDICTS CLINICAL OUTCOMES IN HEART 
FAILURE : 
   Insights Regarding the Role of Xanthine Oxidase and Uric Acid 
in Disease Pathophysiology : 
   In the current issue of circulation, Anker and Colleagues54 report 
that elevated levels of uric acid predict mortality and the need for heart 
transplantation in patients with congestive heart failure. Serum 
concentrations of uric acid added important prognostic information 
alone and when combined with measures of cardiac function (ejection 
fraction) and patient  functional status (maximal oxygen consumption 
with exercise) and were independent of renal function, serum sodium, 
Blood urea, diuretic usage, and patient age. 
   A consideration of the mechanism of uric acid production and 
metabolism offers insight into the relationship between uric acid levels 
and Heart failure outcomes. Moreover, uric acid levels may reflect 
xanthine oxidase pathway activity, which has the potential to 
myocardial energetics and myofilament  calcium sensitivity. 55 
POTENTIAL MECHANISMS FOR INCREASED URIC ACID IN 
HEART FAILURE : 
   Uric acid is a metabolic byproduct of purine metabolism. Serum 
uric acid  may increase in the failing circulation because of increased 
generation, decreased excretion, or a combination of the 2 factors. 
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There are several possible contributors to increased uric acid 
production in Heart failure, including increased abundance and activity 
of xanthine oxidase, increased conversion of xanthine dehydrogenase 
to xanthine oxidase, or increased xanthine oxidase substrate resulting 
from enhanced ATP breakdown to adenosine and hypoxanthine. As 
uric acid is excreted primarily by the kidney, decreased renal perfusion 
could lead to increased uric acid levels. To the extent that Heart failure 
leads to  tissue ischemia  and a rise in serum lactate, renal uric acid 
excretion can be further impaired as lactate competes with urate  via an 
organic anion exchanger in the proximal tubule. 56 
PATHOPHYSIOLOGICAL ROLE OF THE XANTHINE OXIDASE 
PATHWAY IN HEART FAILURE: 
   The elevation in serum uric acid may reflect increased xanthine 
oxidase pathway activity and in turn the generation of superoxide and 
resultant oxidative stress via the xanthine oxidase  system. 57 Xanthine 
oxidase is upregulated within the heart in both experimental and 
human heart failure. Much had previously been made of the difficulty in 
identifying xanthine oxidase within the hearts of certain mammalian 
species, including humans,58 nevertheless, it is clear that xanthine 
oxidase, which is produced in highest abundance in the liver and gut 
may circulate in the blood and adhere to endothelium in distant sites. 
Moreover, xanthine oxidase is expressed in cardiac myocytes, as 
 35
shown by immunohistochemistry and may participate in intracrine 
signaling. 
PATHOPHYSIOLOGICAL ROLE OF URIC ACID IN HEART 
FAILURE : 
   Beyond xanthine oxidase activity, recent experimental studies 
suggest that uric acid itself may have a role in cardiovascular and renal 
pathophysiology. This might seem surprising, as uric acid can function 
as an antioxidant both by itself and by promoting superoxide 
dismutase activity,59 and might therefore be considered potentially 
protective. However, uric acid potently stimulates vascular smooth 
muscle cell proliferation in vitro, an effect mediated by stimulation of 
mitogen-activated protein kinases, cyclooxygenase –2, and platelet 
derived growth factor. 60 
CLINICAL UTILITY OF URIC ACID MEASUREMENTS : 
   From a clinical perspective, the current study raises the issue of 
whether serum uric acid levels should be routinely measured in Heart 
failure  patients. 61 Indeed this is likely to be a controversial issue, and 
one which will require evaluation in the context of measurement of 
brain natriuretic peptide (BNP), a serum marker that also possesses 
prognostic and diagnostic value in Heart failure patients. Much in the 
same way as BNP has been evaluated, it will be of great value to 
 36
assess whether uric acid levels change in response to Heart failure 
therapy in a manner that predicts clinical outcome. 
   Whether or not uric acid levels are ready for clinical use, the 
observation that uric acid levels possess prognostic information adds 
an extremely intriguing finding to mounting evidence that xanthine 
oxidase and uric acid play pathophysiological roles in Heart failure and 
its precursor, hypertension. Indeed, the amassing data have led to the 
planning of a clinical trial entitled A phase II – III prospective, 
Randomized, Double – Blind, Placebo – Controlled Efficacy and safety 
study of Oxypurinol Added to Standard theraphy in patients with NYHA 
class III- IV Congestive Heart Failure (OPT-CHF) initiated in 2003, which 
will test clinical outcomes using a composite endpoint comprising 
measures of heart failure morbidity,exercise capacity, and mortality. 
The findings of Anker and colleagues, therefore, not only bring to light 
a potentially new diagnostic test but also provide a novel line of 
evidence that the xanthine oxidase pathway  and / or uric acid  itself 
may be of pathophysiological importance in  heart  failure progression. 
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MATERIALS AND METHODS 
STUDY POPULATION: 
 This study was conducted in the Department of medicine and 
Department of cardiology Thanjavur medical College, Thanjavur, Tamil 
Nadu during the period of August 2004 to August 2006. Total number of 
patients  included in this study were 100. There were 78 males 22 
females  patients ranging from 23  years to 83 years. 
STUDY DESIGN : 
This study is a prospective study. This study is aimed to assess 
the prognostic role of serum Uric acid level following Acute Myocardial 
Infarction and correlating the levels with short term complications. 
This study included 100 patients of Acute Myocardial Infarction 
of which patient who had a normal Uric acid level were taken as a 
control and the rest who had elevated Uric acid level were taken up as 
study population. 
In both groups the complications and short term outcome were 
compared. 
INCLUSION CRITERIA : 
 Patients with a diagnosis of Acute ST Elevation Myocardial 
Infarction were entered into the study. A definite diagnosis of Acute ST 
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Elevation Myocardial Infarction  was made if the patients satisfied the 
following criteria: 
1. A History of typical retrosternal compressive chest pain lasting 
for more than 30 minutes, not relieved by rest or nitrates. 
2. Typical ECG changes of Acute ST Elevation Myocardial 
Infarction  (ST,T changes in two contiguous leads)  
EXCLUSION CRITERIA : 
1. Patients with elevated renal parameters. 
2. Patients with Gout. 
3. Patients with History of chronic alcoholism. 
4. Patients with previous History of Ischemic Heart Disease and 
on Aspirin theraphy. 
5. Patients with Diabetes mellitus. 
6. Patients on Diuretic theraphy. 
Above patients were excluded because the coexisting disease or 
drug theraphy might itself produce a high Uric acid level.  
Very late presentations of patients more than 72 hours also 
excluded since uric acid level tends to fall subsequently (Journal of 
the Indian Medical Association 1977 Sep1).   
 
 39
VARIABLES RECORDED DURING THE STUDY: 
 Routine History, physical examination, Routine laboratory 
investigations were performed in all subjects. 
1. Presenting History : 
¾ Duration of  chest discomfort 
¾ Associated symptoms like sweating, palpitations, 
dyspnoea. 
¾ Time of onset of symptoms. 
2. Killip’s  classification on  admission : 
3. Admission Electrocardiogram (ECG) : 
a) Site of infarction  :  Anterior, Inferior, Lateral, Right 
ventricular, Global. 
b) No of leads with Q waves or ST Elevation. 
4. Laboratory Investigations : 
¾ Full Blood count 
¾ Blood Sugar, Blood Urea, Serum creatinine, Serum 
Electrolytes. 
¾ Serum Uric acid level on admission. 
¾ Urine Albumin, Sugar, Deposits. 
¾ Serum cholestrol. 
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Qualifying patients received thrombolytic theraphy with 1.5 
million units of Streptokinase followed by Heparin for 5 – 7 days. 
Assessment of left ventricular ejection fraction by 
Echocardiography was performed either on day 4 or 5 of 
hospitalisation in most patients or earlier if clinically indicated. 
URIC ACID  ESTIMATION : 
Immediately after admission blood sample of 3cc was drawn by 
venipuncture and transferred to dry plain bottle and taken to 
biochemistry laboratory. The method used for analysis is Enzymatic 
method (Uricase method) by using Auto analyser. 
 In our laboratory, values taken as normal range62  
 For Males   : 3.4   - 7.0 mg/dl 
 For Females  : 2.4  -  6.0 mg/dl 
METHODOLOGY: 
 Methods using URICASE, the enzyme that catalyzes the 
oxidation of uric acid to allantoin are most specific.63 The simplest of 
these methods measures the differential absorption of uric acid and 
allantoin at 293 nm. 64 The difference in absorbance before and after 
incubation with URICASE is proportional to the uric acid concentration. 
This method has been proposed as candidate  reference method.65 
This method was done in our study. This is the most specific method. 
 41
FOLLOW UP : 
 All the patients were followed up for a period of 10 days . During 
follow up any changes in  killip’s classification, features of Cardiac 
failure, Arrhythmias and any Mortality were noted in both group of 
patients.  Routine daily  physical examination was done. ECG’s were 
taken daily and additional investigations carried out if necessary. 
Patients were discharged at 11th day if they were stable otherwise their 
hospital stay was prolonged. 
 Framingham criteria for Heart failure like JVP elevation ,  Basal 
Rales, Acute pulmonary edema, S3 gallop, Tachycardia (>120/mt), 
Lower extremity edema were used in this study  for making a diagnosis 
of CCF. 66 
 All patients were subjected to continuous cardiac monitoring 
with the aim of identifying various Arrhythmias . In this study the 
incidence of  Arrhythmias like Atrial  fibrillation, Atrial  flutter, 
Paroxysmal Supra Ventricular Tachycardia,  Sustained and illsustained 
Ventricular Tachycardia and Ventricular fibrillation were noted  in both 
group of patients. Patients presented with beningn ventricular 
premature beats were not included into the Arrhythmias category. 
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RESULTS & OBSERVATIONS 
 The study population consisted of 100 patients with 78 males 
and 22  females. All patients belonged to places around Thanjavur 
District. All patients were admitted in  I.C.C.U  initially for 5 days then 
cared in adjoining intermediate cardiac care  ward and discharged after 
an average period of 10 days provided there were no complications. 
 The various observations  made in this study are depicted below  
 
AGE INCIDENCE (Fig :1) 
 
Table : 1 
 
Age in years 21-30 31-40 41-50 51-60 61-70 71-80 81-90 
No of cases 2 10 20 37 22 7 2 
 
 
 
SEX INCIDENCE (Fig :2) 
 
Table : 2 
 
Sex No of cases Percentage 
Males 78 78 
Females 22 22 
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CONTROL AND STUDY POPULATION (Fig :3&4) 
 
 
Table  : 3 
 
 
Sex Control Population  (53) Study population(47) 
Male 43 (81%) 35 (74%) 
Female 10 (19%) 12 (26%) 
 
 
 
DISTRIBUTION OF PATIENTS ACCORDING TO URIC ACID LEVEL & 
SEX – IN TOTAL POPULATION  (Fig :5) 
 
Table : 4  
 
 
Uric 
acid 
(mg/dl) 
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 7.0-7.9 8.0-8.9 9.0-9.9 
Male 4 5 10 23 21 10 5 
Female 2 1 5 8 3 2 1 
 
 
 
 
 
 
 
 
 44
KILLIP CLASS IN HIGH SERUM URIC ACID POPULATION                             
(STUDY GROUP)  (Fig :6) 
Table : 5 
 
Killip Class I & II III & IV 
No of patients  19 28 
 Percentage of patients with 
 Killip I & II in high serum  =    19 x 100 
 uric acid population             47 
      =   40 % 
 
 Percentage of patients with 
 High killip class III & IV in          =    28 x 100 
High serum uric acid population        47 
=   60 % 
 
KILLIP CLASS IN NORMAL SERUM URIC ACID POPULATION  
(CONTROL GROUP) (Fig :7) 
Table : 6 
 
Killip Class I & II III & IV 
No of Patients 40 13 
  Percentage of patients with 
Killip I & II in normal uric  = 40 x 100 
acid  population         53 
      = 75% 
 
Percentage of patients with 
Killip III & IV in normal uric   = 13 x 100 
acid  population        53 
      = 25 % 
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TYPE OF INFARCTION   
 
Table : 7 
 
 
TYPE IN HIGH SERUM URIC 
ACID POPULATION 
IN NORMAL SERUM 
URIC ACID 
POPULATION 
AWMI 19 18 
ASMI 5 11 
IWMI 5 12 
Infero posterior MI  6 7 
IWMI + RVMI 4 3 
Lateral wall MI 6 1 
Global MI 2 1 
 
 
INCIDENCE OF HEART FAILURE IN TOTAL POPULATION (Fig :8) 
 
Table : 8 
 
 
Total no of patients studied No of patients who developed 
Heart failure 
100 41 
 
ie. 41 % of patients  in the study  developed Heart failure . 
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HEART FAILURE ACCORDING TO SEX (Fig :9) 
 
Table : 9 
 
 
Total no of Heart 
failure patients 
Male (%) Female (%) 
41 33 (80%) 8 (20 %) 
 
PROPORTION OF  HEART FAILURE CONTRIBUTED BY PATIENTS  
WITH NORMAL & HIGH SERUM URIC ACID LEVEL (Fig :10) 
Table : 10 
 
Total no of patients 
with Heart failure 
No of patients  with 
high serum uric acid 
No of patients with 
normal serum uric 
acid 
41 30 11 
 
 Contribution of patients with 
 High Serum uric acid level to   = 30 x 100 
  Heart failure          41 
       = 73 % 
 
 Contribution of patients with  
 Normal serum uric acid level to  = 11 x 100 
  Heart failure          41 
       = 27 % 
 
 It is observed that patients with high uric acid level  contributes 
73% to the total incidence of Heart failure. 
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INCIDENCE OF HEART FAILURE IN PATIENTS WITH HIGH SERUM 
URIC ACID LEVEL  (STUDY GROUP) (Fig :11) 
Table : 11 
 
No of patients with high serum 
uric acid level 
No of patients with Heart failure 
47 30 
  
 Incidence  =  30  x 100 
                              47 
    = 64 % 
 ie. 64 % of patients with high uric acid level  developed Heart 
failure. 
ie. 36 % of patients with high uric acid level didn’t develop Heart 
failure. 
INCIDENCE OF HEART FAILURE IN PATIENTS WITH NORMAL SERUM 
URIC ACID LEVEL  (CONTROL GROUP) (Fig :12) 
 
Table : 12 
 
No of patients with normal serum 
uric acid level 
No of patients with Heart failure 
53 11 
 Incidence  = 11 x 100 
                     53 
    = 21 % 
ie. 21 % of patients with normal uric acid level developed Heart 
failure. 
Ie. 79 % of  patients with normal uric acid level didn’t develop 
Heart failure. 
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  ECHOCARDIOGRAM  ANALYSIS (Fig :13) 
 
Table : 13 
 
 
Echo     findings In high uric acid 
patients 
In normal uric acid 
patients 
Normal LV systolic 
function 
6 36 
Mild LV dysfunction 14 9 
Moderate LV 
dysfunction 
13 3 
Severe LV 
dysfunction 
3 2 
Total 36 50 
 
 
 
INCIDENCE OF ARRHYTHMIAS (IN TOTAL POPULATION) (Fig :14) 
 
Table : 14 
 
 
Total no of patients studied No of patients who developed 
Arrhythmias 
100 7 
 
ie. 7 % of patients in the study developed Arrhythmias. 
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ARRHYTHMIAS ACCORDING  TO SEX (Fig :15) 
 
Table : 15 
 
 
Total no of Arrythmia 
patients 
Male (%) Female (%) 
7 6 (86%) 1 (14 %) 
  
 
PROPORTION OF ARRHYTHMIAS CONTRIBUTED BY PATIENTS WITH 
NORMAL & HIGH SERUM URIC ACID LEVEL  (Fig :16) 
 
Table : 16 
 
Total no of patients 
with Arrhythmias 
No of patients with 
high serum uric acid  
No of patients with 
normal serum uric 
acid 
7 5 2 
  Contribution of patients with 
 High serum uric acid level to  = 5 x 100 
   Arrhythmias                   7 
       = 71% 
 
 Contribution of  patients with 
 Normal serum uric acid level to  = 2 x 100 
   Arrhythmias         7 
       = 29 % 
 It is observed that patients with high uric acid level contributes 
71% to the total incidence of Arrhythmias. 
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INCIDENCE OF ARRHYTHMIAS IN PATIENTS WITH HIGH SERUM  URIC 
ACID LEVEL (STUDY GROUP) (Fig :17) 
 
Table : 17  
 
No of patients with high serum 
uric acid level 
No of patients  with Arrhythmias 
47 5 
 Incidence    = 5 x 100 
           47 
     = 11%  
 ie. 11 % of patients with high uric acid level  developed 
Arrhythmias. 
 
 
INCIDENCE OF ARRHYTHMIAS IN PATIENTS WITH NORMAL URIC 
ACID LEVEL (CONTROL GROUP) (Fig :18) 
Table : 18 
 
No of patients with normal uric 
acid level 
No of patients with Arrhythmias 
53 2 
 
 Incidence    = 2 x 100 
          53  
    = 4 % 
 
 ie. 4% of patients with normal uric acid level  developed 
Arrhythmias. 
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INCIDENCE OF MORTALITY (IN  TOTAL  POPULATION ) (Fig :19) 
 
 
Table : 19 
 
 
 Total no of patients studied No of patients died 
100 15 
 
ie  15 % of patients in the study died. 
 
 
 
 
 
`MORTALITY ACCORDING TO SEX (Fig :20) 
 
 
Table : 20 
 
 
Total no of deaths Male (%) Female (%) 
15 14 (93%) 1 (7%) 
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PROPORTION OF MORTALITY  CONTRIBUTED BY PATIENTS WITH 
NORMAL  & HIGH  SERUM URIC ACID LEVEL   (Fig :21) 
Table : 21 
Total no of deaths No of patients with 
high uric acid level 
No of patients with 
normal uric acid level
15 12 3 
 
 Contribution of patients with 
 High serum  uric acid level  to Mortality = 12 x 100 
                 15 
        = 80 % 
 Contribution of patients with 
 Normal  serum  uric acid level  to Mortality = 3 x 100 
            15 
        = 20% 
 It is observed that patients with high uric acid level contributes 
80% to the total incidence  of mortality. 
INCIDENCE OF MORTALITY IN PATIENTS WITH HIGH SERUM URIC 
ACID LEVEL ( STUDY GROUP) (Fig :22) 
Table : 22 
 
No of patients with high serum 
uric acid level 
No of  deaths 
47 12 
 Incidence  = 12 x 100 
        47 
   = 26 % 
 ie. 26 % of  patients with high uric acid level  died in  the study. 
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INCIDENCE OF MORTALITY IN PATIENTS WITH NORMAL  SERUM 
URIC ACID LEVEL (CONTROL GROUP) (Fig :23) 
Table : 23 
No of patients with normal uric 
acid level 
No of deaths 
53 3 
 
 Incidence   = 3 x 100 
         53 
    = 6 % 
 ie. 6 % patients with normal uric acid level  died in the study. 
 
 
MORTALITY IN AGE GROUP (Fig :24) 
 
Table : 24 
 
Age Total no of patients 
41-50 3 
51-60 6 
61-70 4 
71-80 1 
81-90 1 
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DISCUSSION 
 Total number of patients included in this study was100, out of 
which 47  patients had elevated level of uric acid above normal range  
following Acute Myocardial Infarction. 
AGE : 
 Of the 100 patients 2 patients were in the age group of 21-30 
years, 10 patients were in the age group of 31-40 years, 20 patients 
were in the age group of  41 –50 years, 37 patients were in the age 
group of 51-60 years, 22 patients were in the age group  of 61 –70 
years, 7 patients were in the age group of 71-80 years and 2 patients  
were in the age group of 81 –90 years ( Table1 & Fig 1). 
SEX : 
 In this study number of male patients were 78, while number of 
female patients were 22.  (Table 2 & Fig 2) 
CONTROL & STUDY POPULATION: 
 Out of 100 patients studied 53  patients had Normal uric acid 
level and they were taken up as control. Of which 43 (81%) were males 
and 10 (19%) were females. The rest 47 patients had elevated uric acid 
level and they were taken up as study group. Of which 35(74%) were 
males and 12 (26%) were females. (Table 3, Fig : 3 & 4). Both were 
compared with various out comes.    
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CLINICAL STATUS- KILLIP CLASS & URIC ACID: 
 In this study 43 patients presented with Killip class I, 16 patients 
presented with Killip class II, 18 patients presented with Killip class III, 
23 patients presented with Killip class IV. Killip class III & IV were taken 
as high risk category in this study and evaluated whether high uric acid 
concentration after myocardial infarction correlated with this high risk 
Killip class.  
 When clinical status of patients based on killip class I to IV and 
uric acid were analysed,  the following observations were made. 
 In the control group who had normal serum uric acid level, 75 % 
belonged to I & II Killip  class  and only 25% belonged to Killip  class III 
& IV as against the study 40 % Killip class I & II and 60% Killip class III 
& IV which parallely correlates  with the elevated uric acid level and the 
clinical status (Table 5 & 6. Fig 6 & 7)  
Our study correlates with kojima S, Sakamoto et al., (American 
journal of cardiology, 2005 Aug 15) who also showed patients who had 
high uric acid level belonged to higher Killip class. Hence uric acid can 
also be used as an predictor of prognosis, but also a predictor of 
severity. 
TYPE OF INFARCTION & URIC ACID : 
 In this study 37 patients presented with Anterior Wall Myocardial 
Infarction (AWMI) of which 19 patients had high uric acid level, 16 
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patients presented with   Antero Septal Myocardial Infarction (ASMI), of 
which 5 patients had high uric acid level, 17 patients presented with 
Inferior Wall Myocardial Infarction (IWMI), of which 5 patients had high 
uric acid level, 13 patients presented with Infero posterior wall  
Myocardial Infarction, of which 6 patients had high uric acid level , 7 
patients presented with inferior and Right Ventricular Myocardial 
Infarction (RVMI), of which  4 patients had high uric acid level, 7 
patients presented with Lateral Wall Myocardial Infarction , of which 6 
patients had high  uric acid level, 3 patients presented with Global 
Myocardial Infarction ,of  which 2 patients had high uric acid level. 
 When areas of infarction and uric acid levels were observed, an 
increased level of uric acid in Anterior  wall Myocardial Infarction was 
noted. This cannot be taken into statistical account, because the 
overall incidence of Anterior  Wall  Myocardial Infarction itself was high 
(Table 7). 
 HEART FAILURE : 
 41 out of 100 patients in this study had Heart failure in the post 
Myocardial Infarction period. So the incidence of heart failure was 41 
%. Of which  33(80%) were males, 8 (20%) were females.(Table 8&9, Fig 
8&9) 
 It was observed that among 41 Heart failure patients, 30 patients 
had high uric  acid  level and 11 patients had normal uric acid level. So 
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patients who had high uric acid level and normal uric acid level 
contributed to 73% and 27 % respectively to Heart failure. (Table 10, 
Fig. 10) 
 It was also found that 30 patients out of 47 patients with high 
uric acid level had Heart  failure amounting to an incidence of 64 % 
Heart failure in this group. While only 11 out of 53 patients  with normal 
uric acid level had Heart failure. ie. Only 21% of patients with normal 
uric acid level had Heart failure. (Table 11&12, Fig 11 &12) 
 The   above figures suggest that the occurrence of Heart failure 
is high in patients with high uric acid level. Our studies comparable 
with other studies who showed similar findings and elevated serum 
uric acid level is an early predictor of short term outcome.  
 Kojima S. Sakamoto et al, (American journal of cardiology  2005 
Aug 15) Anker SD, Doehner W et.al., ( Circulation 2003, Apr 22; 
circulation 2003 Nov 25) Sakai H, Tsutamoto T et. al.,(J cardiol.2006 
May), Joshua M, Hare MD  et.al., (circulation 2003, American Heart 
association), Virendra singh, RK Goyal et.al., ( Journal of the Indian 
Medical association 1977 Sep 1) studies support this study. Their 
studies  revealed that serum uric acid level reflects  circulatory 
xanthine oxidase activity and oxidative stress production. Increased 
serum uric acid level has been identified in patients who have 
congestive cardiac failure and is a marker of poor prognosis in such 
patients. 
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ECHOCARDIOGRAM: 
 In high uric acid population, 6 patients had normal LV function, 
14 patients had mild LV dysfunction, 13 patients had moderate LV 
dysfunction, 3 patients had severe LV dysfunction. 
 In normal uric acid level population, 36 patients had normal LV 
function, 9 patients had mild LV dysfunction, 3 patients had moderate 
LV dysfunction, 2 patients had severe LV dysfunction. (Table 13, Fig 
13). 
 Patients who had elevated serum  uric acid level in the study 
group showed moderate to severe LV dysfunction (34%) This has 
correlated with an initial observation of cardiac failure which was 27% 
in this population. 
 So serum uric acid level can also be correlated with 
Echocardiographic cardiac dysfunction later, retrospectively with 
clinical findings earlier.  
 So uric acid level can be used as a definite predictor of cardiac 
failure.  
ARRHYTHMIAS : 
 7 out of 100 patients  developed Arrhythmias  in this study. So 
the incidence of Arrhythmias was 7% of which 6 (86%) were males, 1 
(14%) was female. 3 patients had ventricular tachycardia and 4 patients 
had supra ventricular tachycardia (Table 14 & 15, Fig 14&15). 
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 It was observed that among 7 Arrhythmias 5 patients had high 
uric level and 2 patients had normal uric acid level. So patients who 
had high uric acid level and normal uric acid level contributed to 71% 
and 29% respectively to Arrhythmias (Table 16 , Fig 16) . 
 It was also found that 5 patients out of 47 patients with high uric 
acid level had Arrhythmias amounting to an incidence of 11% 
Arrhythmias in this group. While only 2 out of 53 patients with normal 
uric acid level had Arrhythmias. ie.only  4 % of patients with normal 
uric acid level had Arrhythmias. (Table 17&18, Fig 17&18). 
 The above findings suggest that the occurrence of Arrhythmias 
is also high in patients with high uric acid level. 
 This observation can be matched with the outcome of a large 
randomized double blind placebo control clinical trial “Oxypurinol 
theraphy for CHF” conducted in 2003, which could establish a 
beneficial effect for oxypurinol in reducing the incidence of 
Arrhythmias and other adverse cardiac events by lowering serum uric 
acid level. 
 The above trial & our trial tells there is a high incidence of 
Arrhythmias when there is an elevated serum uric acid level and  it is 
hypothetical an increased uric acid level may be arrhythmogenic. 
Further studies are  needed to conclude. 
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MORTALITY : 
 15 out of 100 patients  died due to their cardiac ailments in this 
study. This amounts to mortality rate of 15% of which 14 ( 93%) were 
males, 1 (7%) was female. (Table 19&20, Fig 19&20).  
 To find out the prognostic significance of elevated uric acid level 
following Acute Myocardial Infarction, mortality rate in patients with 
normal and high uric acid level were separately calculated.  
 It was observed that among 15 deaths 12 deaths were 
contributed by patients with high uric  acid levels and 3 deaths by 
those who had normal uric acid levels. Thus 80% of death in post 
infarction period occurred in those who had a high uric acid level and 
only 20% in those who had a normal uric acid level. (Table 21, Fig 21) 
 It was also found that 12 out of 47 patients with high uric acid 
level died. This implies a mortality rate of 26%.Like wise a mortality rate 
of 6 % was observed for patients with normal uric acid level following 
MyocardiaI Infarction (Table 22&23, Fig 22&23). 
 This striking difference in the mortality figures for  both group of 
patients implies uric acid level can be used as a predictor of mortality 
following Myocardial Infarction.  
 It this study ,4 patients died on the day of admission, 6 patients 
died on 2nd day, 4 patients died on 3rd day, 1 patient died on 7th day. 
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 Out of 15 deaths, 3 patients (20%) were in the age group of 41-50 
years, 6 patients (40%) were in the age group of 51-60 years, 4 patients 
(26%) were in the age group of 61-70 years, 1 patient (7%) was in the 
age group of 71-80 years and 1 patient (7%) was in the age group of 81-
90 years. (Table 14, Fig 24) 
 Kojima S, Sakamoto et. al.,(American journal of cardiology 2005 
Aug 15)  Fang J, Alderman M H et. al., (Serum uric acid and 
cardiovascular mortality, JAMA 2000) Bengtsson C, Lapidus L et.al., 
(Acta Med Scand 1998) Freedman DS, Williamson DF et.al., (Relation of 
serum uric acid to mortality and Ischemic Heart disease Am. J. 
Epidemiol 1995)   Culleton BF, Lassonmia et.al ., ( Serum uric acid and 
risk of cardiovascular disease and death Ann. Intern. Med July 6. 1999) 
studies supports this study. This study  revealed that patients who 
developed short term adverse events like mortality following 
Myocardial Infarction had high uric acid concentrations. 
 Our study also parallels with previous authors and uric acid can 
be used as a good predictor of mortality. 
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CONCLUSION 
 
1. Measuring serum Uric acid level is one of the predictable 
prognostic indicator in Acute Myocardial Infarction and one of 
the early and short term predictor. 
2. A high serum Uric acid level correlated with short term mortality 
in Acute Myocardial Infarction. 
3. Elevated serum Uric acid is strongly associated with cardiac 
Arrhythmias as against controls and can be used as an 
immediate prognostic indicator in Acute Myocardial Infarction. 
4. Elevated serum Uric acid level may be Arrhythmogenic. Further 
studies require to confirm and to treat. 
5. There is a strong correlation of elevated serum Uric acid and 
cardiac failure 
6. Patients with high Uric acid level belonged  to higher Killip class 
status(III & IV) . 
7. Elevated Uric acid level had a objective correlation with Echo 
cardiographic evaluation of LV dysfunction. 
8. Our study is compatible with other studies done with Uric acid 
as a predictor. 
. 
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PROFORMA 
 
 
NAME :      AGE :   SEX: 
OCCUPATION :     I.P.NO: 
ADDRESS :      D.O.A : 
        D.O.D : 
SYMPTOMS AT THE TIME OF ADMISSION:  
     CHEST PAIN           DYSPNOEA           S   SWEATING       PALPITATIONS 
   OLIGURIA               PAIN & SWELLING IN JOINTS 
PAST HISTORY : 
     RENAL DISEASE          GOUT                CHRONIC ALCOHOLISM 
   IHD           D   DIABETES            ASPIRIN & DIURETIC THERAPHY 
ECG : 
 
KILLIP’S CLASSIFICATION :  I     II     III    IV 
THROMBOLYSED :      NOT THROMBOLYSED : 
CLINICAL EXAMINATION :   a. PR : 
       b. BP : 
    c. JVP elevation :    Yes / No 
    d. Pedal edema  :    Yes / No 
    e. Basal Rales    :     Yes / No 
INVESTIGATIONS : 
  a. Hb % :                    b. TC :   c. DC : 
    d. URINE :      ALB  :                 SUGAR :                 DEPOSITS : 
      e. BLOOD SUGAR :         f. BLOOD UREA: 
    g. SERUM CREATININE : 
      h. SERUM ELECTROLYTES :                 Na+ :                        K+ : 
       i. SERUM URIC ACID LEVEL ON ADMISSION : 
       j. SERUM CHOLESTEROL : 
      k. ECHOCARDIOGRAM : 
ADVERSE CARDIAC EVENTS: 
a. CARDIAC FAILURE : 
b. ARRHYTHMIAS 
c. SHOCK 
d. DEATH  
HOSPITAL STAY : 
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DISTRIBUTION ACCORDING TO URIC ACID LEVEL & SEX 
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KILLIP CLASS – HIGH URIC  ACID  POPULATION                   
(STUDY GROUP)  
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HEART FAILURE PATIENTS – HIGH URIC ACID POPULATION 
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ECHOCARDIOGRAM ANALYSIS 
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URIC ACID STATUS IN PATIENTS WITH ARRHYTHMIAS  
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ARRHYTHMIAS – HIGH URIC ACID POPULATION 
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OUTCOME IN TERMS OF MORTALITY – TOTAL POPULATION  
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SCHEMATIC REPRESENTATION OF PURINE METABOLISM  
